Suppr超能文献

血管生成宿主防御肽 AG-30/5C 和缓激肽 B 受体拮抗剂 Icatibant 是肥大细胞中 MRGPRX2 的 G 蛋白偏向激动剂。

Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells.

机构信息

Department of Pathology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104.

Department of Pathology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104

出版信息

J Immunol. 2019 Feb 15;202(4):1229-1238. doi: 10.4049/jimmunol.1801227. Epub 2019 Jan 16.

Abstract

AG-30/5C is an angiogenic host defense peptide that activates human mast cells (MC) via an unknown mechanism. Using short hairpin RNA-silenced human MC line LAD2 and stably transfected RBL-2H3 cells, we demonstrate that AG-30/5C induces MC degranulation via Mas-related G protein-coupled receptor X2 (MRGPRX2). Most G protein-coupled receptors signal via parallel and independent pathways mediated by G proteins and β-arrestins. AG-30/5C and compound 48/80 induced similar maximal MC degranulation via MRGPRX2, which was abolished by pertussis toxin. However, compound 48/80 induced a robust β-arrestin activation as determined by transcriptional activation following arrestin translocation (Tango), but AG-30/5C did not. Overnight culture of MC with compound 48/80 resulted in reduced cell surface MRGPRX2 expression, and this was associated with a significant decrease in subsequent MC degranulation in response to compound 48/80 or AG-30/5C. However, AG-30/5C pretreatment had no effect on cell surface MRGPRX2 expression or degranulation in response to compound 48/80 or AG-30/5C. Icatibant, a bradykinin B receptor antagonist, promotes MC degranulation via MRGPRX2 and causes pseudoallergic drug reaction. Icatibant caused MC degranulation via a pertussis toxin-sensitive G protein but did not activate β-arrestin. A screen of the National Institutes of Health Clinical Collection library led to the identification of resveratrol as an inhibitor of MRGPRX2. Resveratrol inhibited compound 48/80-induced Tango and MC degranulation in response to compound 48/80, AG-30/5C, and Icatibant. This study demonstrates the novel finding that AG-30/5C and Icatibant serve as G protein-biased agonists for MRGPRX2, but compound 48/80 signals via both G protein and β-arrestin with distinct differences in receptor regulation.

摘要

AG-30/5C 是一种血管生成的宿主防御肽,通过未知机制激活人类肥大细胞 (MC)。使用短发夹 RNA 沉默的人类 MC 系 LAD2 和稳定转染的 RBL-2H3 细胞,我们证明 AG-30/5C 通过 Mas 相关 G 蛋白偶联受体 X2 (MRGPRX2) 诱导 MC 脱颗粒。大多数 G 蛋白偶联受体通过 G 蛋白和β-arrestin 介导的平行和独立途径信号转导。AG-30/5C 和化合物 48/80 通过 MRGPRX2 诱导相似的最大 MC 脱颗粒,该作用被百日咳毒素消除。然而,化合物 48/80 诱导了强大的β-arrestin 激活,如通过 arrestin 易位(Tango)后的转录激活所确定的,但 AG-30/5C 没有。MC 与化合物 48/80 overnight culture 导致细胞表面 MRGPRX2 表达减少,这与对化合物 48/80 或 AG-30/5C 反应的后续 MC 脱颗粒显著减少相关。然而,AG-30/5C 预处理对化合物 48/80 或 AG-30/5C 反应的细胞表面 MRGPRX2 表达或脱颗粒没有影响。Icatibant,一种缓激肽 B 受体拮抗剂,通过 MRGPRX2 促进 MC 脱颗粒,并引起假性过敏药物反应。Icatibant 通过百日咳毒素敏感的 G 蛋白引起 MC 脱颗粒,但不激活β-arrestin。国家卫生研究院临床收藏库文库的筛选导致鉴定白藜芦醇为 MRGPRX2 的抑制剂。白藜芦醇抑制化合物 48/80 诱导的 Tango 和化合物 48/80、AG-30/5C 和 Icatibant 反应的 MC 脱颗粒。本研究表明了一个新的发现,即 AG-30/5C 和 Icatibant 作为 MRGPRX2 的 G 蛋白偏向激动剂,但化合物 48/80 通过 G 蛋白和β-arrestin 信号转导,受体调节存在明显差异。

相似文献

3
Inhibition of MRGPRX2 but not FcεRI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist.
Front Immunol. 2022 Oct 6;13:1033794. doi: 10.3389/fimmu.2022.1033794. eCollection 2022.
4
Murepavadin, a Small Molecule Host Defense Peptide Mimetic, Activates Mast Cells MRGPRX2 and MrgprB2.
Front Immunol. 2021 Jun 23;12:689410. doi: 10.3389/fimmu.2021.689410. eCollection 2021.
5
Human Mast Cell Line HMC1 Expresses Functional Mas-Related G-Protein Coupled Receptor 2.
Front Immunol. 2021 Mar 15;12:625284. doi: 10.3389/fimmu.2021.625284. eCollection 2021.
10
Thimerosal induces skin pseudo-allergic reaction via Mas-related G-protein coupled receptor B2.
J Dermatol Sci. 2019 Sep;95(3):99-106. doi: 10.1016/j.jdermsci.2019.07.007. Epub 2019 Jul 24.

引用本文的文献

1
Allergic and other adverse reactions to drugs used in anesthesia and surgery.
Anesthesiol Perioper Sci. 2023;1(2):16. doi: 10.1007/s44254-023-00018-2. Epub 2023 Jun 14.
2
Biased agonism of G protein-coupled receptors as a novel strategy for osteoarthritis therapy.
Bone Res. 2025 May 12;13(1):52. doi: 10.1038/s41413-025-00435-y.
3
The MRGPR family of receptors in immunity.
Immunity. 2024 Jan 9;57(1):28-39. doi: 10.1016/j.immuni.2023.12.012.
4
GRK2 differentially regulates FcεRI and MRGPRB2-mediated responses in mast cells.
Front Immunol. 2023 Mar 29;14:1155777. doi: 10.3389/fimmu.2023.1155777. eCollection 2023.
5
Inflammation and Organ Injury the Role of Substance P and Its Receptors.
Int J Mol Sci. 2023 Mar 24;24(7):6140. doi: 10.3390/ijms24076140.
6
Hypersensitivity reactions to small molecule drugs.
Front Immunol. 2022 Nov 10;13:1016730. doi: 10.3389/fimmu.2022.1016730. eCollection 2022.
7
Inhibition of MRGPRX2 but not FcεRI or MrgprB2-mediated mast cell degranulation by a small molecule inverse receptor agonist.
Front Immunol. 2022 Oct 6;13:1033794. doi: 10.3389/fimmu.2022.1033794. eCollection 2022.
8
β-arrestin-1 and β-arrestin-2 Restrain MRGPRX2-Triggered Degranulation and ERK1/2 Activation in Human Skin Mast Cells.
Front Allergy. 2022 Jul 15;3:930233. doi: 10.3389/falgy.2022.930233. eCollection 2022.
10
Inhibition of Orai Channel Function Regulates Mas-Related G Protein-Coupled Receptor-Mediated Responses in Mast Cells.
Front Immunol. 2022 Jan 20;12:803335. doi: 10.3389/fimmu.2021.803335. eCollection 2021.

本文引用的文献

1
Mast cell activators as novel immune regulators.
Curr Opin Pharmacol. 2018 Aug;41:89-95. doi: 10.1016/j.coph.2018.05.004. Epub 2018 May 26.
3
The contribution of mast cells to bacterial and fungal infection immunity.
Immunol Rev. 2018 Mar;282(1):188-197. doi: 10.1111/imr.12623.
8
In silico design of novel probes for the atypical opioid receptor MRGPRX2.
Nat Chem Biol. 2017 May;13(5):529-536. doi: 10.1038/nchembio.2334. Epub 2017 Mar 13.
9
Distinct conformations of GPCR-β-arrestin complexes mediate desensitization, signaling, and endocytosis.
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2562-2567. doi: 10.1073/pnas.1701529114. Epub 2017 Feb 21.
10
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents.
Front Cell Infect Microbiol. 2016 Dec 27;6:194. doi: 10.3389/fcimb.2016.00194. eCollection 2016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验